NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,640,096 | +7.6% | 720,749 | +176.6% | 0.01% | +20.0% |
Q2 2023 | $10,815,564 | +1086891.4% | 260,616 | +1474.6% | 0.01% | +400.0% |
Q1 2023 | $995 | -91.7% | 16,551 | -89.8% | 0.00% | -85.7% |
Q4 2022 | $11,949 | -95.8% | 162,900 | +4257.9% | 0.01% | – |
Q3 2022 | $284,000 | -95.1% | 3,738 | -95.5% | 0.00% | -100.0% |
Q2 2022 | $5,813,000 | +2352.7% | 83,635 | +2827.4% | 0.00% | – |
Q1 2022 | $237,000 | -97.6% | 2,857 | -97.8% | 0.00% | -100.0% |
Q4 2021 | $9,738,000 | +2582.6% | 129,698 | +4051.7% | 0.01% | – |
Q3 2021 | $363,000 | -85.3% | 3,124 | -72.0% | 0.00% | -100.0% |
Q2 2021 | $2,477,000 | -40.3% | 11,167 | -64.4% | 0.00% | -33.3% |
Q1 2021 | $4,151,000 | -79.1% | 31,400 | -72.6% | 0.00% | -78.6% |
Q4 2020 | $19,849,000 | +352.1% | 114,708 | +190.8% | 0.01% | +180.0% |
Q3 2020 | $4,390,000 | -72.5% | 39,443 | -85.3% | 0.01% | -77.3% |
Q2 2020 | $15,950,000 | +2392.2% | 268,979 | +2729.6% | 0.02% | +1000.0% |
Q1 2020 | $640,000 | -60.5% | 9,506 | -56.2% | 0.00% | -33.3% |
Q3 2019 | $1,622,000 | -57.5% | 21,697 | -64.1% | 0.00% | -50.0% |
Q2 2019 | $3,820,000 | -34.3% | 60,415 | -49.9% | 0.01% | -33.3% |
Q1 2019 | $5,811,000 | +775.2% | 120,627 | +852.0% | 0.01% | +800.0% |
Q3 2018 | $664,000 | -86.2% | 12,671 | -91.7% | 0.00% | -83.3% |
Q2 2018 | $4,803,000 | -11.0% | 153,465 | -38.0% | 0.01% | -14.3% |
Q1 2018 | $5,394,000 | -44.9% | 247,424 | -48.9% | 0.01% | -50.0% |
Q4 2017 | $9,788,000 | +29.6% | 484,569 | +27.4% | 0.01% | +16.7% |
Q3 2017 | $7,550,000 | +5798.4% | 380,359 | +2302.2% | 0.01% | – |
Q1 2017 | $128,000 | -76.4% | 15,834 | -75.1% | 0.00% | -100.0% |
Q3 2016 | $543,000 | +96.7% | 63,527 | +168.2% | 0.00% | 0.0% |
Q2 2016 | $276,000 | -45.6% | 23,683 | -32.3% | 0.00% | 0.0% |
Q1 2016 | $507,000 | -59.2% | 35,008 | -37.0% | 0.00% | -66.7% |
Q4 2015 | $1,243,000 | – | 55,589 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |